Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors

• Verfasst von: Zschäbitz, Stefanie [VerfasserIn]
• Verfasst von: Lasitschka, Felix [VerfasserIn]
• Verfasst von: Jäger, Dirk [VerfasserIn]
• Verfasst von: Grüllich, Carsten [VerfasserIn]
• Titel: Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors
• Verf.angabe: S. Zschäbitz, F. Lasitschka, D. Jäger and C. Grüllich
• E-Jahr: 2016
• Jahr: 30 March 2016
• Umfang: 5 S.
• Fussnoten: Gesehen am 19.01.2018
• Titel Quelle: Enthalten in: Annals of oncology
• Ort Quelle: Amsterdam [u.a. : Elsevier, 1990
• Jahr Quelle: 2016
• Band/Heft Quelle: 27(2016), 7, Seite 1356-1360
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdw146
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1567366805

Abstract

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [e-mail] outcome of patients with platinum refractory germ cell cancer who relapse after or are no candidates for stem-cell transplantation is dismal. No significant progress has been made within the last years. The use of anti-PD-1 antibodies has led to complete remissions and long-term disease control in patients with non-small-cell lung cancer, renal cell carcinoma, and malignant melanoma with metastasized disease [1-3]. Recently, PD-L1 expression in testicular germ-cell tumor samples has been described [4, 5]....We report on the clinical course of four heavily pretreated patients with platinum refractory germ-cell tumors for whom no more curative standard existed and who received checkpoint inhibitors (anti-PD-1 antibodies). Detailed characteristics of pretreatment schedules are given in Table 1 (patients 3 and 4)...